Amarin Announces FDA Approval of Vascepa Capsules for the Reduction of Triglyceride Levels in Adult Patients With Severe Hypertriglyceridemia
Amarin Corporation plc (NASDAQ: AMRN) announced Thursday that the U.S. Food and Drug Administration has approved VascepaTM (icosapent ethyl) capsules (formerly known as AMR101) as an adjunct to diet to reduce triglyceride levels in adult patients with severe (TG greater than or equal to 500mg/dL) hypertriglyceridemia (very high triglycerides). Amarin submitted the New Drug Application for the use of Vascepa in this indication in September 2011.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.